AVITA Medical Reports FY25 Revenue Of $71.6M, Q4 Revenue Of $17.6M; Sees FY26 Revenue Of $80M-$85M

AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025. The Company also provided its preliminary outlook for fiscal year 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. Pacific Time (Thursday, January 15, 2026, at 12:15 p.m. Australian Eastern Daylight Time). The webcast can be accessed through AVITA Medical's website at: https://ir.avitamedical.com/events-and-presentations

Preliminary financial and business update:

• Total net revenues of approximately $17.6 million in the fourth quarter of 2025, compared to $18.4 million in the fourth quarter of 2024.
• Total revenues of approximately $71.6 million for full year 2025, compared to $64.3 million for full year 2024, representing an increase of approximately 11%, within the Company's revised revenue guidance for the year.
• Existing debt refinanced, securing up to $60 million of committed capital under a new credit facility with Perceptive Advisors to strengthen the Company's capital structure and support long-term growth.
• Full year 2026 revenue expected in the range of approximately $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 revenue.
• Cohealyx-I study fully enrolled, and PermeaDerm-I study surpassed 75% enrollment, in December 2025; data from both clinical studies expected later in 2026.